Danaher Corporation is rated Buy with a target price of $250, implying 10.5% upside from $226.25. DHR's strong Q3 execution featured 4.5% revenue growth, margin expansion to 37.2%, and robust free ...

Australia has become one of the fastest-growing destinations for clinical research. With high-quality healthcare infrastructure, diverse patient populations, and streamlined ethics approvals that can ...

Eli Lilly announced plans to construct a $6 billion pharmaceutical manufacturing facility in Huntsville, aiming to enhance ...

CHA Biotech subsidiary Matica Biolabs signed a contract to manufacture medical developer TiCARos' new CAR-T cancer therapy ...

Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.

Just after market close on Monday, Dyne announced that it has launched an underwritten public offering of $300 million worth ...

Abivax is preparing a regulatory submission in the U.S. in the second half of 2026, provided an ongoing maintenance trial ...

Seventy-three pharmaceutical, biotechnology and medical device companies from mainland China filed for IPOs in Hong Kong this year, a review by BioWorld found. In the second half of 2025, 43 new ...

For pharmaceutical firms, watching the lucrative patents on their top-selling drugs expire has long been part of the business ...

ASH's 2025 meeting ended with strong multiple myeloma data from J&J, a new treatment for a rare disorder, and strains on a ...

TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech ...

Today we discuss why comparing U.S. vaccine policy to Europe’s is a red herring, why the revolving door at the FDA between ...